2012-11-29 14:38:32 -
SEATTLE, WA -- (Marketwire) -- 11/29/12 --
Atossa Genetics, Inc : www.atossagenetics.com/
. (NASDAQ: ATOS) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP : client.irwebkit.com/AtossaGenetics/management-team
, chairman, CEO and president of Atossa Genetics, Inc., will present at the 5th Annual LD Micro Conference : www.ldmicro.com/
on Wednesday, December 5, 2012, at 10:00 AM Pacific Time, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
Dr. Quay's presentation will focus on the Company's novel approaches to breast cancer risk assessment and prevention, 2013 growth initiatives for its first year as a public company, and its unique investment thesis.
A link : client.irwebkit.com/AtossaGenetics/events
to the live audio webcast with slides of the presentation can be accessed on Atossa's website. After clicking on the webcast link : client.irwebkit.com/AtossaGenetics/events
, visitors will be directed to the proper conference's registration page. After completing the required fields and clicking "Register," visitors will then be brought to the dedicated webcast page. A replay of the webcast will be available for 90 days after the presentation and can be accessed at the same web address.
The LD Micro Conference is a two-day conference organized by LD Micro, a by-invitation only newsletter firm that provides micro-cap research for its clients. The LD Micro Conference focuses on undervalued micro-cap companies in a broad range of industries. A record 580 investors attended the 2011 event. Investors interested in attending the conference should call 408-457-1042 or e-mail Chris@ldmicro.com
: mailto:Chris@ldmicro.com , or visit the conference website : www.ldmicro.com/
About Atossa Genetics, Inc.
Atossa Genetics, Inc. : www.atossagenetics.com/
, The Breast Health Company, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer : www.atossagenetics.com/resources_the_role_of_naf_hyperplasia_pro ..
up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
The National Reference Laboratory for Breast Health (NRLBH) : www.nrlbh.com/
, a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented ForeCYTE Breast Health Test : www.nrlbh.com/testing-services/risk-assessment.php
, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear : womenshealth.gov/publications/our-publications/fact-sheet/pap-te ..
and the ArgusCYTE Breast Health Test : www.nrlbh.com/testing-services/recurrence-monitoring.php
, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
Add to Digg : digg.com/submit?phase=2&url= www2.marketwire.com/mw/release_html_b1?release_id=959749
Bookmark with del.icio.us : del.icio.us/post?v=4&noui&jump=close&url= www2.marketwire.com/mw/release_html_b1?release_id=959749
Add to Newsvine : www.newsvine.com/_tools/seed&save?u= www2.marketwire.com/mw/release_html_b1?release_id=959749
Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
800-351-3902 ext. 103
Email Contact : www2.marketwire.com/mw/emailprcntct?id=812044BD8FCCD4E1
Matthew D. Haines (Investors and Media)
MBS Value Partners
Email Contact : www2.marketwire.com/mw/emailprcntct?id=F78D9EF06578E2A0